Login / Signup

Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study.

Donald L GilbertTanya K MurphyJoseph JankovicCathy L BudmanKevin J BlackRoger M KurlanKeith A CoffmanJames T McCrackenJorge JuncosJon E GrantRichard E Chipkin
Published in: Movement disorders : official journal of the Movement Disorder Society (2018)
Ecopipam reduced tics and was well tolerated. This placebo-controlled study of ecopipam supports further clinical trials in children and adolescents with Tourette syndrome. © 2018 International Parkinson and Movement Disorder Society.
Keyphrases
  • clinical trial
  • double blind
  • placebo controlled
  • case report
  • young adults
  • phase ii
  • study protocol
  • phase iii
  • open label
  • smoking cessation
  • phase ii study